Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Der Internist|June 14, 2008
[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?]A Seeringer, J KirchheinerBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|October 3, 2006
[State of the art of pharmacogenetic diagnostics in drug therapy]J Kirchheiner, A Seeringer, J BrockmöllerMolecular Psychiatry|April 7, 2010
CYP2D6 in the brain: genotype effects on resting brain perfusionJ Kirchheiner, A Seeringer, A L Godoy, et al.Diabetes, Obesity & Metabolism|October 28, 2010
Genetic variants of the insulin receptor substrate-1 are influencing the therapeutic efficacy of oral antidiabeticsA Seeringer, S Parmar, A Fischer, et al.The Pharmacogenomics Journal|December 14, 2011
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicityS Parmar, C Schumann, S Rüdiger, et al.Klinische Padiatrie|March 18, 2014
Feasibility of intensive multimodal therapy in infants affected by rhabdoid tumors - experience of the EU-RHAB registryA Seeringer, K Bartelheim, K Kerl, et al.Clinical Pharmacology and Therapeutics|January 10, 2008
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patientsC Wyen, U Fuhr, D Frank, et al.Pageof 1